MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
85.69
+4.60
+5.67%
Opening 14:32 10/15 EDT
OPEN
81.30
PREV CLOSE
81.09
HIGH
86.48
LOW
79.06
VOLUME
846.77K
TURNOVER
--
52 WEEK HIGH
104.00
52 WEEK LOW
10.94
MARKET CAP
5.39B
P/E (TTM)
-20.4352
1D
5D
1M
3M
1Y
5Y
1D
Kodiak Sciences put volume heavy and directionally bearish
TipRanks · 1d ago
Kodiak Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
Kodiak Sciences Price Target Raised to $126.00/Share From $96.00 by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126
Benzinga · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)
TipRanks · 3d ago
Kodiak Sciences price target raised to $126 from $96 at H.C. Wainwright
TipRanks · 3d ago
Weekly Report: what happened at KOD last week (1005-1009)?
Weekly Report · 3d ago
Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)
TipRanks · 10/05 14:00
More
About KOD
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.